Last updated: February 15, 2026
Overview
NDC 00093-0756 refers to a specific drug formulation listed in the FDA’s National Drug Code (NDC) database. This NDC corresponds to Oxycodone Hydrochloride Extended-Release (ER) and Acetaminophen. It is used primarily for moderate to severe pain management.
Market Size and Demand
The demand for opioid analgesics, including oxycodone ER with acetaminophen, remains substantial due to ongoing analgesic needs in acute, chronic, and palliative care settings. The U.S. market for opioids was valued at approximately $8.9 billion in 2022, with oxycodone products accounting for roughly 40% ($3.56 billion). Although regulatory pressure aims to curb misuse, demand persists in drug allowance and hospital settings.
Competitive Landscape
Key players include Purdue Pharma, Teva, Mylan (now Viatris), and Endo Pharmaceuticals. Major formulations compete primarily based on formulation release profiles, abuse-deterrent features, and pricing strategies.
Market Drivers
- Chronic pain management: Pain accounts for more than 20% of adult visits to physicians.
- Postoperative care: Widely used in hospital protocols.
- Regulatory environment: Tighter restrictions impact supply and distribution, but the demand persists at institutional levels.
Pricing Dynamics
Pricing varies significantly based on formulation, manufacturer, and distribution channels. The average wholesale price (AWP) for a typical 30-day supply of oxycodone ER with acetaminophen ranges from $150 to $230.
Generic formulations tend to be priced lower, around $135 to $180 for comparable supplies. Branded versions, especially abuse-deterrent formulations, can exceed $250 or more.
| Price Component |
Range (per 30-day supply) |
Notes |
| Generic oxycodone ER/acetaminophen |
$135 - $180 |
Widely available, low-cost formulations |
| Branded, abuse-deterrent formulations |
$200 - $250+ |
Higher price due to formulation technology |
| Institutional pricing |
Slightly lower |
Negotiated prices for hospitals or clinics |
Price Projections (Next 3-5 Years)
| Year |
Expected Price Range |
Key Factors |
| 2023 |
$140 - $200 |
Ongoing generic competition, regulatory adjustments |
| 2024 |
$135 - $195 |
Increased scrutiny could push prices down or stabilize |
| 2025 |
$130 - $185 |
Further generic proliferation, potential price compression |
| 2026 |
$125 - $180 |
Regulatory trends favoring generics over branded products |
Note: Abuse-deterrent formulations are likely to retain higher prices, especially if new formulations are introduced with improved safety features.
Regulatory and Policy Impact
Interstate and federal regulations influence market dynamics, including:
- Rescheduling of opioids to Schedule II, impacting supply and prescriptions.
- Increased DEA oversight and prescription monitoring programs.
- Pressure to develop abuse-deterrent formulations, which typically command premium pricing.
Potential Market Entrants and Disruptors
- New abuse-deterrent formulations from existing generic manufacturers.
- Biotech companies exploring non-opioid analgesics with similar efficacy.
- Policy shifts favoring non-addictive pain management alternatives.
Key Takeaways
- The drug associated with NDC 00093-0756 occupies a significant segment in the opioid pain management market.
- Prices for generic formulations are expected to trend downward over the next five years due to increased competition.
- Branded, abuse-deterrent variants may sustain higher prices but face potential regulatory and market pressures.
- The market's growth is constrained by regulatory reforms but remains robust due to ongoing pain management needs.
FAQs
-
What is the current market size for oxycodone ER products?
Estimated at over $3.5 billion annually in the U.S., representing a substantial share of pain management drugs.
-
How will regulatory changes impact the price of this drug?
Tightening restrictions could reduce supply costs but may also limit prescribing, leading to price stabilization or slight declines.
-
Are abuse-deterrent formulations significantly more expensive?
Yes. They usually retail at least 10-20% higher than standard generics, reflecting added safety features.
-
What factors could alter the price trend over the next five years?
Introduction of non-opioid alternatives, policy shifts favoring safety, and patent expirations of branded versions.
-
How does generic competition influence pricing?
Generic proliferation typically causes prices to decline, with some variability based on formulation complexity.
Citations
[1] IQVIA. (2022). Pharmaceutical Market Data.
[2] FDA. Drug Product Data Files.
[3] Medicare and Medicaid Claims Data, 2022.
[4] United States Patent and Trademark Office (USPTO). Patent filings related to abuse-deterrent formulations.
[5] RAND Corporation. (2020). Opioid Market and Policy Analysis.
